Citius Oncology Inc (CTOR) Stock Price, Quote & News

Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 967 6677

Address:

11 Commerce Drive, First Floor, Cranford, United States

Waffels May. 12 at 4:33 PM

$CTOR

0 · Reply

TwongStocks May. 12 at 1:31 PM

$CTOR Now that they have finally been able to secure a decent amount of funding, it looks like they are ready to finalize the hiring of the commerical team. https://www.linkedin.com/posts/chad-lachapelle_hi-everyone-so-excited-to-announce-the-posting-share-7459931651175837696-ppzQ?utm_source=screenshot_social_share 5 months after launch. Better late than never I guess.

0 · Reply

donein12 May. 11 at 5:09 PM

$CTOR Sadly the 1st quarter financials are coming out in days with a full 3 months of sales results, and clearly no one believes the numbers will be good with shares down .0388 (-4.28%).

0 · Reply

TwongStocks May. 8 at 8:51 PM

$CTXR $CTOR One interesting feature of the third amendment. CTXR could acquire more shares of CTOR by converting a portion of the $3.8M Note into shares of CTOR at $0.90 per share. : "voluntary conversion feature allowing the Company, subject to Citius Oncology’s approval, to convert all or a portion of the outstanding principal into shares of common stock at a conversion price equal to $0.90 per share. All other terms of the Promissory Note remain the same." Full conversion of the $3,800,111 at $0.90 would be an additional 4,222,345 shares to CTXR.

1 · Reply

TwongStocks May. 8 at 8:42 PM

$CTXR SEC filing https://www.sec.gov/ix?doc=/Archives/edgar/data/1506251/000121390026053916/ea0289731-8k_citius.htm Summary • After the spinoff, CTXR gave $CTOR $3,800,111 in the form of a promissory note. • CTOR was originally supposed to repay CTXR after raising at least $10M. It was later revised to repayment after CTOR raised at least $30M in total funding. Then it was revised so that repayment would happen after CTOR raised at least $50M in total funding. • This third amendment now changes the repayment date to 91 days after CTOR pays off their loans to Avenue.

0 · Reply

NYC100 May. 7 at 4:29 PM

$CTOR you should sell

0 · Reply

whathappenedtomyaccount May. 7 at 3:00 PM

$CTOR 30-50% dilution. Hundreds of millions in milestone payments. Commercial success just means more milestone payments come due. Understand that shareholders are last in line to benefit here. Lenny has proven over the years that he loathes the retail investor. He even said it once in interview. NFA. DYODD. I'm done with this shit ticker.

0 · Reply

whathappenedtomyaccount May. 7 at 2:49 PM

$CTOR This for example, @TwongStocks

1 · Reply

erichartmann May. 7 at 1:14 AM

$CTOR $CTXR @TwongStocks I’m shocked.. Why are you still here?!? Always appreciated your posts but Lenny is 100% a shister - Borderline criminal. GO EXEL!

2 · Reply

JackCampbell May. 6 at 4:23 PM

$CTXR $CTOR In my opinion, the intention behind the recent capital raises is to soon file an NDA application with the FDA for Mino-Lok!

2 · Reply

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

2026-04-29T14:53:58.000Z - 13 days ago

Market Cap	79.80M
Revenue (ttm)	0.00
Net Income (ttm)	-24.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.26

Volume	50,100
Avg Vol	264,734
Day's Range	N/A - N/A
Shares Out	88.28M
Stochastic %K	48%
Beta	3.56
Analysts	Strong Sell
Price Target	$6.00